samedan logo
 
 
 
spacer
home > ebr > winter 2001 > intrabodies - valuable tools for target validation
PUBLICATIONS
European Biopharmaceutical Review

Intrabodies - Valuable Tools for Target Validation

As more and more genomes become sequenced, the number of novel proteins with unknown function is steadily increasing. Consequently, a considerable interest exists to characterise the function of many gene products and to validate them as potential drug targets in particular disease pathways. Both gene knockout and antisense techniques are employed for this purpose, but they have their limitations. Intrabodies present an attractive alternative to modulate protein function and analyse the effects. Moreover, they can also be employed to target specific domains of the protein. However, the stability of an intrabody is often greatly impaired by the reducing intracellular conditions in the cell that prevent the formation of disulfide bridges. In this article we review a number of examples for the intracellular use of antibodies and discuss selection procedures for the identification of functional intrabodies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Kirsten E. Mundt, Business Development, ESBATech AG

Kirsten Mundt PhD is a Senior Scientist at ESBATech AG, a start-up biotechnology company based in Zurich, Switzerland. She has recently been appointed Project Manager for the company's new business development sector. Kirsten graduated from the University of Dundee, UK, with an honours degree in Biochemistry and went on to gain a PhD from the University of Lausanne in Switzerland. Kirsten's extensive research has centred on molecular biology and biochemistry, with a particular focus on oncology. Her experience has led to conference speaking and academic lecturing, and her work has been published in numerous publications within the biomedical field.
spacer
Dr Kirsten E. Mundt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement